Adjuvant activity of multimolecular complexes based on Glycyrrhiza glabra saponins, lipids, and influenza virus glycoproteins

被引：22

作者：

Alexyuk, P. G. ^{[1
]}

Bogoyavlenskiy, A. P. ^{[1
]}

Alexyuk, M. S. ^{[1
]}

Turmagambetova, A. S. ^{[1
]}

Zaitseva, I. A. ^{[1
]}

Omirtaeva, E. S. ^{[1
]}

Berezin, V. E. ^{[1
]}

机构：

[1] Res & Prod Ctr Microbiol & Virol, 105 Bogenbai Batyr St, Alma Ata 050010, Kazakhstan

来源：

ARCHIVES OF VIROLOGY | 2019年 / 164卷 / 07期

关键词：

VACCINE ADJUVANTS; ISCOMS; QUIL;

D O I：

10.1007/s00705-019-04273-2

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Numerous studies have shown that immunostimulatory complexes containing Quil-A saponin and various antigens are effective in stimulating the immune response and can be used as vaccine preparations for animals and humans. However, Quil-A saponin possesses toxicity and haemolytic activity. In the present work, a saponin-containing preparation named Glabilox was isolated from the roots of a Glycyrrhiza glabra L. plant by high-performance liquid chromatography (HPLC). The results showed that Glabilox has no toxicity or haemolytic activity and can form stable immunostimulatory complexes. Subcutaneous immunization of mice with an immunostimulating complex containing Glabilox and H7N1 influenza virus antigens stimulated high levels of humoral and cellular immunity. Vaccination of chickens with the same immunostimulating complex protected 100% of the animals after experimental infection with a homologous virus. Comparative studies showed that the immunogenic and protective activity of immunostimulatory complexes containing Quil-A and immunostimulatory complexes containing Glabilox are comparable to each other. The results of these studies indicated that Glycyrrhiza glabra saponins show great promise as safe and effective adjuvants.

引用

页码：1793 / 1803

页数：11

共 48 条

[1]

Allison AC, 1998, DEV BIOL STAND, V92, P3

[2]

[Anonymous], 2007, EXPERT REV VACCINES, V6, P654

[3] GLOBAL HEALTH SECURITY AGENDA IMPLEMENTATION: A CASE FOR COMMUNITY ENGAGEMENT [J].

Armstrong-Mensah, Elizabeth A. ;

Ndiaye, Serigne M. .

HEALTH SECURITY, 2018, 16 (04) :217-223

[4] New viral vaccines [J].

Arvin, AM ;

Greenberg, HB .

VIROLOGY, 2006, 344 (01) :240-249

[5]

Aucouturier J, 2000, ANN NY ACAD SCI, V916, P600, DOI 10.1111/j.1749-6632.2000.tb05343.x

[6] Recent progress in adjuvant discovery for peptide-based subunit vaccines [J].

Azmi, Fazren ;

Fuaad, Abdullah Al Hadi Ahmad ;

Skwarczynski, Mariusz ;

Toth, Istvan .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (03) :778-796

[7] CONTROLLED ORGANIZATION OF MULTIMOLECULAR COMPLEXES OF ENVELOPED VIRUS GLYCOPROTEINS - STUDY OF IMMUNOGENICITY [J].

BEREZIN, VE ;

ZAIDES, VM ;

ISAEVA, ES ;

ARTAMONOV, AF ;

ZHDANOV, VM .

VACCINE, 1988, 6 (05) :450-456

[8] SAPONIN AND OTHER HEMOLYSINS (VITAMIN-A, ALIPHATIC-AMINES, POLYENE ANTIBIOTICS) AS ADJUVANTS FOR SRBC IN THE MOUSE - EVIDENCE FOR A ROLE FOR CHOLESTEROL-BINDING IN SAPONIN ADJUVANTICITY [J].

BOMFORD, R .

INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1980, 63 (02) :170-177

[9]

Brugmann M, 1997, DEUT TIERARZTL WOCH, V104, P196

[10]

CANDELA JLF, 1958, B SOC CHIM BIOL, V40, P503

← 1 2 3 4 5 →